{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:10:21Z","timestamp":1793985021156,"version":"4.8.0"},"reference-count":36,"publisher":"Rockefeller University Press","issue":"11","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.rupress.org\/terms\/"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":279,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer\u2019s Association","doi-asserted-by":"crossref","award":["AARF-16-443265"],"award-info":[{"award-number":["AARF-16-443265"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100016608","name":"Rainwater Charitable Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016608","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS095773"],"award-info":[{"award-number":["R01NS095773"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tau SILK Consortium"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012513","name":"Coins for Alzheimer\u2019s Research Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012513","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,11,2]]},"abstract":"<jats:p>Highly sensitive and specific plasma biomarkers for Alzheimer\u2019s disease (AD) have the potential to improve diagnostic accuracy in the clinic and facilitate research studies including enrollment in prevention and treatment trials. We recently reported CSF tau hyperphosphorylation, especially on T217, is an accurate predictor of \u03b2-amyloidosis at asymptomatic and symptomatic stages. In the current study, we determine by mass spectrometry the potential utility of plasma p-tau isoforms to detect AD pathology and investigate CSF and plasma tau isoforms\u2019 profile relationships. Plasma tau was truncated as previously described in CSF. CSF and plasma measures of p-tau-217 and p-tau-181 were correlated. No correlation was found between CSF and plasma on total-tau levels and pS202 measures. We found p-tau-217 and p-tau-181 were highly specific for amyloid plaque pathology in the discovery cohort (n = 36, AUROC = 0.99 and 0.98 respectively). In the validation cohort (n = 92), p-tau-217 measures were still specific to amyloid status (AUROC = 0.92), and p-tau-181 measures were less specific (AUROC = 0.75).<\/jats:p>","DOI":"10.1084\/jem.20200861","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T02:21:47Z","timestamp":1593051707000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":433,"title":["Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease"],"prefix":"10.1084","volume":"217","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4937-2860","authenticated-orcid":true,"given":"Nicolas R.","family":"Barth\u00e9lemy","sequence":"first","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St. Louis, MO 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-2614","authenticated-orcid":true,"given":"Kanta","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St. Louis, MO 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7639-8727","authenticated-orcid":true,"given":"Chihiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St. Louis, MO 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7729-1702","authenticated-orcid":true,"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[{"name":"Department of Neurology, Washington University School of Medicine, St. Louis, MO 1"},{"name":"Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 2"},{"name":"Charles F. and Joanne Knight Alzheimer\u2019s Disease Research Center, Washington University School of Medicine, St. Louis, MO 3"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"key":"2023072622171225400_bib1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","article-title":"Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases","volume":"91","author":"Bacioglu","year":"2016","journal-title":"Neuron"},{"key":"2023072622171225400_bib2","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.jalz.2015.08.063","article-title":"Mass spectrometry follow-up of t181, s199, s202, t205, and T217 tau phosphorylation in cerebrospinal fluid from patients revealed a specific Alzheimer\u2019s disease pattern","volume":"11","author":"Barth\u00e9lemy","year":"2015","journal-title":"Alzheimers Dement"},{"key":"2023072622171225400_bib3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1021\/acs.jproteome.5b01001","article-title":"Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity","volume":"15","author":"Barth\u00e9lemy","year":"2016","journal-title":"J. Proteome Res"},{"key":"2023072622171225400_bib4","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy, N.R., R.J.Bateman, P.Marin, F.Becher, C.Sato, S.Lehmann, and A.Gabelle. 2017. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-\u03b2 pathology. bioRxiv. https:\/\/doi.org\/10.1101\/226977 (Preprint posted November 30, 2017).","DOI":"10.1101\/226977"},{"key":"2023072622171225400_bib5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jalz.2018.06.024","article-title":"MASS SPECTROMETRY\u2013BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD","volume":"14","author":"Barth\u00e9lemy","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023072622171225400_bib6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fnagi.2019.00121","article-title":"Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer\u2019s Disease","volume":"11","author":"Barth\u00e9lemy","year":"2019","journal-title":"Front. Aging Neurosci"},{"key":"2023072622171225400_bib7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat. Med."},{"key":"2023072622171225400_bib8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","article-title":"Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer\u2019s disease and PET amyloid-positive patient identification","volume":"12","author":"Barth\u00e9lemy","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"2023072622171225400_bib9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med"},{"key":"2023072622171225400_bib10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/neu.2015.4333","article-title":"Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid \u03b2 up to 90 Days after Traumatic Brain Injury","volume":"34","author":"Bogoslovsky","year":"2017","journal-title":"J. Neurotrauma"},{"key":"2023072622171225400_bib11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/BF02850342","article-title":"Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results","volume":"23","author":"Bulut","year":"2006","journal-title":"Adv. Ther"},{"key":"2023072622171225400_bib12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","article-title":"Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease","volume":"137","author":"Cicognola","year":"2019","journal-title":"Acta Neuropathol"},{"key":"2023072622171225400_bib13","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12885-019-5287-z","article-title":"The prognostic value of the\u00a0Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases","volume":"19","author":"Darlix","year":"2019","journal-title":"BMC Cancer"},{"key":"2023072622171225400_bib14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/archneur.64.3.noc60123","article-title":"Cerebrospinal fluid tau\/\u03b2-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults","volume":"64","author":"Fagan","year":"2007","journal-title":"Arch. Neurol"},{"key":"2023072622171225400_bib15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007901","article-title":"Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease","volume":"6","author":"Fagan","year":"2014","journal-title":"Sci. Transl. Med"},{"key":"2023072622171225400_bib16","doi-asserted-by":"publisher","first-page":"942","DOI":"10.15252\/msb.20156297","article-title":"Revisiting biomarker discovery by plasma\u00a0proteomics","volume":"13","author":"Geyer","year":"2017","journal-title":"Mol. Syst. Biol"},{"key":"2023072622171225400_bib17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat. Med."},{"key":"2023072622171225400_bib18","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nat. Commun."},{"key":"2023072622171225400_bib19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188802","article-title":"Increased levels of plasma total tau in adult Down syndrome","volume":"12","author":"Kasai","year":"2017","journal-title":"PLoS One"},{"key":"2023072622171225400_bib20","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"2023072622171225400_bib21","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023072622171225400_bib22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"2023072622171225400_bib23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"2023072622171225400_bib24","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/02699052.2012.750752","article-title":"Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma","volume":"27","author":"Neselius","year":"2013","journal-title":"Brain Inj"},{"key":"2023072622171225400_bib25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"2023072622171225400_bib26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ana.24454","article-title":"Age and amyloid effects on human central nervous system amyloid-beta kinetics","volume":"78","author":"Patterson","year":"2015","journal-title":"Ann. Neurol"},{"key":"2023072622171225400_bib27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005615","article-title":"Increased in vivo amyloid-\u03b242 production, exchange, and loss in presenilin mutation carriers","volume":"5","author":"Potter","year":"2013","journal-title":"Sci. Transl. Med"},{"key":"2023072622171225400_bib28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat. Med"},{"key":"2023072622171225400_bib29","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ana.24270","article-title":"Amyloid-\u03b2 efflux from the central nervous system into the plasma","volume":"76","author":"Roberts","year":"2014","journal-title":"Ann. Neurol"},{"key":"2023072622171225400_bib30","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jamaneurol.2017.0655","article-title":"Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers","volume":"74","author":"Rubenstein","year":"2017","journal-title":"JAMA Neurol"},{"key":"2023072622171225400_bib31","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau Kinetics in Neurons and the Human Central Nervous System","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"2023072622171225400_bib32","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"key":"2023072622171225400_bib33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","article-title":"Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome","volume":"12","author":"Tatebe","year":"2017","journal-title":"Mol. Neurodegener"},{"key":"2023072622171225400_bib34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat. Med"},{"key":"2023072622171225400_bib35","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/nan.12378","article-title":"Review: Tau in biofluids - relation to pathology, imaging and clinical features","volume":"43","author":"Zetterberg","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol"},{"key":"2023072622171225400_bib36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer\u2019s disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res. Ther"}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20200861\/1789397\/jem_20200861.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20200861\/1789397\/jem_20200861.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T18:18:08Z","timestamp":1690395488000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/217\/11\/e20200861\/151982\/Blood-plasma-phosphorylated-tau-isoforms-track-CNS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11,2]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20200861","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"article-number":"e20200861"}}